Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy

Although stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has become an established standard of care for the treatment of a variety of malignancies, our understanding of normal tissue dose tolerance with extreme hypofractionation remains immature. Since Timmerman initially...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in radiation oncology 2017-07, Vol.27 (3), p.197-208
Main Authors: Pollom, Erqi L., MD, Chin, Alexander L., MD, MBA, Diehn, Maximilian, MD, PhD, Loo, Billy W., Jr, MD, PhD, Chang, Daniel T., MD
Format: Article
Language:English
Subjects:
Abdominal Neoplasms - radiotherapy
Dose Hypofractionation
Hematology, Oncology and Palliative Medicine
Humans
Liver - radiation effects
Lung - radiation effects
Organs at Risk - radiation effects
Radiology
Radiosurgery - adverse effects
Thoracic Neoplasms - radiotherapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has become an established standard of care for the treatment of a variety of malignancies, our understanding of normal tissue dose tolerance with extreme hypofractionation remains immature. Since Timmerman initially proposed normal tissue dose constraints for SBRT in the 2008 issue of Seminars of Radiation Oncology , experience with SBRT has grown, and more long-term clinical outcome data have been reported. This article reviews the modern toxicity literature and provides updated clinically practical and useful recommendations of SBRT dose constraints for extracranial sites. We focus on the major organs of the thoracic and upper abdomen, specifically the liver and the lung.
ISSN:1053-4296
1532-9461
DOI:10.1016/j.semradonc.2017.02.001